Spiera R, Hummers L, Chung L, et al. - This study was attempted to evaluate the safety and effectiveness of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). Researchers performed a randomized, double‐blind, placebo‐controlled, phase II study conducting at 9 SS c clinics in the US. They randomized adults with dcSS c of ≤ 6 years’ duration who were receiving stable standard‐of‐care treatment to receive lenabasum (n = 27) or placebo (n = 15). They further evaluated safety and efficacy at weeks 4, 8, 12, and 16. The data revealed that lenabasum improves efficacy outcomes and underlying disease pathology with a favorable safety profile, despite a short trial duration in a small number of patients in this phase II study in dcSS c,.